United Pharm is about to apply for the regulatory approval of a combo therapy, which combines the antithrombotic ingredient of cilostazol with the dyslipidemia component of rosuvastatin.Industry insiders pay attention to whether Korea United Pharm, which emerged as a significant player in the antith
The government said it would look into whether state-funded developers of Covid-19 vaccines and treatments made any attempts to exaggerate clinical development status or inflate their stock prices. The evaluation, consisting of a team of external experts, will start in January next year after the Ko
AptaBio, a developer of innovative drugs for intractable diseases, said on Tuesday that it will present the treatment effect of APX-NEW, an oxidative stress drug for the treatment of Parkinson's disease, at the Society for Neuroscience (SFN) on Nov.12-16 in San Diego, the U.S.APX-NEW is a drug with
Is it necessary for biopharmaceutical companies to introduce the “ESG (environment, society, and governance) management,” which has emerged as a new corporate keyword for businesses worldwide?If so, how should biopharma firms prepare for “ESG management?”What “ESG management” strategies are global b
Dx&Vx, a Korean molecular diagnostics company, said Wednesday that it recorded 8.6 billion won ($ 6.4 million) in sales in the third quarter, up 82.8 percent from the same period in 2021.The company also registered 412.2 million and 620.8 million won in operating and net profit, down 56.5 and 67.8 p
The Korea Health Industry Development Institute (KHIDI) said on Tuesday that a delegation from Abu Dhabi’s Department of Health International Patient Care Center (DOH IPCC) visited six hospitals in Korea to gauge how much Emiratis patients were satisfied with Korean hospital services. They also disc
Jung Ki-seok, a top adviser to the government's COVID-19 task force, said on Monday that the government was concerned about the low Covid-19 booster vaccination rate during the winter season ahead of the full-fledged Covid-19 recurrence."Summer and winter are different as winter poses extra risks of
Hanmi Science, which recently merged with affiliate Hanmi Healthcare, said it will strengthen its medical device business, including surgical materials.Hanmi Science, a holding company of Hanmi Group, decided to merge with its affiliates, Hanmi Healthcare, in September and completed the merger proce
Some Korean biopharmaceutical companies have benefited from local currency weakening against the dollar in the second half, mainly due to their large proportions of exports, while importers of drug ingredients suffered headwinds.The Korean won has been sliding against the greenback throughout 2022.
Hanmi Pharmaceutical said on Monday that its U.S. partner, Aptose Bioscience, confirmed complete remission in phase 1/2 clinical trials of HM43239, an acute myeloid leukemia (AML) treatment (ingredient: tuspetinib), in all three doses (80 mg, 120 mg, and 160 mg). The trials took place in the U.S. an
Tecentriq (atezolizumab), an anti-PD-L1 drug developed by Roche, has become the first immunotherapy in Korea approved as a postoperative adjuvant treatment for early non-small cell lung cancer (NSCLC) patients.Last Friday, the Ministry of Food and Drug Safety approved the use of Tecentriq as the “po
Severance Hospital and Seoul National University Bundang Hospital (SNUBH) researchers have discovered an indicator that can improve the survival rate of Korean heart transplant patients.When a patient with severe heart failure has to receive a heart transplant, it is important to find the “right hea
Korea Research Institute of Bioscience & Biotechnology (KRIBB) said on Monday that its researchers have discovered proteins to alleviate human inflammation to aid in the diagnosis of inflammatory diseases and the development of therapeutic technologies.Inflammation is a complex immune response that
The International Vaccine Institute (IVI) completed the second week of the three-week-long WHO Global Training Hub for Biomanufacturing (GTH-B) training program with a visit to Celltrion’s factory in Songdo, Incheon, on Friday.This training program is the second WHO GTH-B program following the first
SK Biopharmaceuticals, which targets the U.S. market with its epilepsy treatment, Cenobamate (XCopri in the U.S.), is stepping up the development of follow-up products.The Ministry of Food and Drug Safety approved the phase 3 clinical trial of SK Biopharmaceuticals’ Carisbamate (YKP509) last Thursda
Ildong Pharmaceutical has jumped into developing P-CAB (potassium-competitive acid blockers)-based treatment for gastroesophageal reflux disease (GERD), drawing the industry’s attention to the market once again.Last Thursday, the Ministry of Food and Drug Safety approved the domestic phase 1 trial o
M2N said it has established MGFB, a joint venture between Greenfire Bio (GFB), a U.S. affiliate of M2N and the Mayo Clinic, to jointly research and develop a solid cancer treatment using an anticancer vaccine.Through MGFB, the two parties plan to research an anticancer vaccine, under development by
In the wake of the Itaewon crush tragedy on Oct. 29, many counseling support groups have emerged to help those suffering from post-traumatic stress disorder (PTSD) symptoms.One of the very first groups to offer free counseling services in response to the Itaewon disaster was Adaptable Human Solution
Health officials announced that the government will no longer operate its Incheon treatment center used for foreigners undergoing Covid-19 quarantine from Nov. 30. The government will halt admission at the facility from Nov. 23.The government explained that this is because the number of foreigners u
Medical artificial intelligence (AI) solutions that assist medical professionals’ diagnosis are expanding their domain to skin diseases.LifeSemantics is one of the companies most active in developing AI solutions to diagnose skin diseases. In the K-HOSPITAL 2022 Fair held from Sept. 29 to Oct. 1, th